Havemeyer Place LP Purchases Shares of 6,294 Abbott Laboratories $ABT

Havemeyer Place LP purchased a new stake in Abbott Laboratories (NYSE:ABT) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 6,294 shares of the healthcare product maker’s stock, valued at approximately $789,000.

Several other large investors have also recently bought and sold shares of ABT. 111 Capital bought a new stake in shares of Abbott Laboratories during the 4th quarter worth $325,000. Vestcor Inc lifted its holdings in shares of Abbott Laboratories by 46.6% during the 4th quarter. Vestcor Inc now owns 112,714 shares of the healthcare product maker’s stock worth $14,122,000 after acquiring an additional 35,849 shares during the last quarter. MCF Advisors LLC lifted its holdings in shares of Abbott Laboratories by 27.9% during the 4th quarter. MCF Advisors LLC now owns 5,188 shares of the healthcare product maker’s stock worth $650,000 after acquiring an additional 1,133 shares during the last quarter. First Command Advisory Services Inc. lifted its holdings in shares of Abbott Laboratories by 1.9% during the 4th quarter. First Command Advisory Services Inc. now owns 10,188 shares of the healthcare product maker’s stock worth $1,276,000 after acquiring an additional 186 shares during the last quarter. Finally, Invst LLC lifted its holdings in shares of Abbott Laboratories by 4.9% during the 4th quarter. Invst LLC now owns 2,575 shares of the healthcare product maker’s stock worth $323,000 after acquiring an additional 120 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Insider Transactions at Abbott Laboratories

In other news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on ABT shares. Piper Sandler dropped their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Jefferies Financial Group dropped their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday, April 17th. Bank of America dropped their price objective on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Weiss Ratings downgraded shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, April 24th. Finally, TD Cowen lowered their price target on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.09.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $90.46 on Tuesday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $157.57 billion, a PE ratio of 25.34, a P/E/G ratio of 1.52 and a beta of 0.63. The firm has a fifty day simple moving average of $92.52 and a two-hundred day simple moving average of $108.88. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.